Anna Rosati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna Rosati has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Alessandro Padovani
Neurology Clinic (A.R., A.T., A.P.), Pathology Service (P.L.P., M.C., D.M.), Medical Oncology (S.G., E.L.S.), Neurosurgery Department (M.C.), and Radiotherapy Department (S.M.M., M.B.), Spedali Civili, University of Brescia, Brescia, Italy
2 shared publicationsAlice Todeschini
Neurology Clinic (A.R., A.T., A.P.), Pathology Service (P.L.P., M.C., D.M.), Medical Oncology (S.G., E.L.S.), Neurosurgery Department (M.C.), and Radiotherapy Department (S.M.M., M.B.), Spedali Civili, University of Brescia, Brescia, Italy
2 shared publicationsMarco Cenzato
Neurology Clinic (A.R., A.T., A.P.), Pathology Service (P.L.P., M.C., D.M.), Medical Oncology (S.G., E.L.S.), Neurosurgery Department (M.C.), and Radiotherapy Department (S.M.M., M.B.), Spedali Civili, University of Brescia, Brescia, Italy
2 shared publications- Renzo Guerrini
Neuroscience and Human Genetics Department, Meyer Children's Hospital IRCCS, Florence, Italy
2 shared publications Alessandra Cosi
Paediatric Neurology Unit, NEUROFARBA Department, Anna Meyer Children's Hospital, University of Florence, 50139 Firenze, Italy
1 shared publication- Alice Brambilla
Rheumatology Unit-Paediatric Section, NEUROFARBA Department, Anna Meyer Children's Hospital, University of Florence, Pieraccini street, # 24, 50139 Firenze, Italy
1 shared publication
Latest Publications
- 1 May 2017
- Published by Elsevier in Joint Bone Spine
- Vol. 84 (3) , 353-356
Mycophenolate mofetil as induction and long-term maintaining treatment in childhood: Primary angiitis of the central nervous system
- 1 May 2017
- Published by Elsevier in Joint Bone Spine
- Vol. 84 (3) , 353-356
Mycophenolate mofetil as induction and long-term maintaining treatment in childhood: Primary angiitis of the central nervous system
- 1 February 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 440, 31-35
Dried blood spot assay for the quantification of phenytoin using Liquid Chromatography-Mass Spectrometry
- 1 February 2015
- Published by Elsevier in Clinica Chimica Acta
- Vol. 440, 31-35
Dried blood spot assay for the quantification of phenytoin using Liquid Chromatography-Mass Spectrometry
- Open Access
- 14 February 2013
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (5) , 618-625
Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme
Glutamine synthetase (GS) is an astrocytic enzyme catalyzing the conversion of glutamate and ammonia to glutamine. Its up-regulation has been related to higher tumor proliferation and poor prognosis in extra-cerebral tumors. We have previously reported a GS deficiency in patients with glioblastoma multiforme (GBM) who also developed epilepsy, which is a favorable prognostic factor in glioma. Here, we investigated the prognostic value of GS expression in patients with GBM with or without epilepsy and its correlation with survival. We conducted a clinical and histopathological study on 83 (52 males) consecutive patients with newly diagnosed GBM. Immunohistochemical expression of GS was scored semi-quantitatively on the basis of cell number, staining intensity, and distribution of immunoreactive cells. Several clinical and neuropathological variables were analyzed in relation to survival and GS expression. Median age at diagnosis was 62 years. At the last evaluation, with a median follow-up of 11.5 months (range, 1.5–58 months), 5 patients (6%) were still alive and 78 (94%) were dead. GS expression patterns in neoplastic cells were inversely correlated to the presence of epilepsy (P < .0001 for intensity and P < .009 for homogeneity of GS distribution, respectively). Univariate analysis showed that RPA score, epilepsy, O6-methylguanine-DNA methyltransferase (MGM)T status, application of Stupp protocol, and GS intensity pattern had a significant impact on survival. Absent/low intensity of GS expression was significantly associated with a longer survival in both uni- (19 vs 8 months; P < .0005) and multivariate (P = .003) analyses. Absent/low-intensity GS expression pattern represents a valuable biomarker of both epilepsy and overall survival in GBM.
- 14 February 2013
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (5) , 618-625
Open AccessGlutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme
Glutamine synthetase (GS) is an astrocytic enzyme catalyzing the conversion of glutamate and ammonia to glutamine. Its up-regulation has been related to higher tumor proliferation and poor prognosis in extra-cerebral tumors. We have previously reported a GS deficiency in patients with glioblastoma multiforme (GBM) who also developed epilepsy, which is a favorable prognostic factor in glioma. Here, we investigated the prognostic value of GS expression in patients with GBM with or without epilepsy and its correlation with survival. We conducted a clinical and histopathological study on 83 (52 males) consecutive patients with newly diagnosed GBM. Immunohistochemical expression of GS was scored semi-quantitatively on the basis of cell number, staining intensity, and distribution of immunoreactive cells. Several clinical and neuropathological variables were analyzed in relation to survival and GS expression. Median age at diagnosis was 62 years. At the last evaluation, with a median follow-up of 11.5 months (range, 1.5–58 months), 5 patients (6%) were still alive and 78 (94%) were dead. GS expression patterns in neoplastic cells were inversely correlated to the presence of epilepsy (P < .0001 for intensity and P < .009 for homogeneity of GS distribution, respectively). Univariate analysis showed that RPA score, epilepsy, O6-methylguanine-DNA methyltransferase (MGM)T status, application of Stupp protocol, and GS intensity pattern had a significant impact on survival. Absent/low intensity of GS expression was significantly associated with a longer survival in both uni- (19 vs 8 months; P < .0005) and multivariate (P = .003) analyses. Absent/low-intensity GS expression pattern represents a valuable biomarker of both epilepsy and overall survival in GBM.
- Open Access
- 1 March 2010
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (3) , 343-346
Efficacy and Safety of Levetiracetam in Patients With Glioma
The incidence of epilepsy in adult patients with glioma is approximately 30%, ranging from 20% to 80%, with the highest frequency of epilepsy in low-grade tumors.1-4 Seizures may be the presenting symptom of a brain tumor, or they may occur later during the disease. Only the recurrence of seizures justifies the diagnosis of epilepsy and the use of anticonvulsants.5
- 1 March 2010
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (3) , 343-346
Open AccessEfficacy and Safety of Levetiracetam in Patients With Glioma
The incidence of epilepsy in adult patients with glioma is approximately 30%, ranging from 20% to 80%, with the highest frequency of epilepsy in low-grade tumors.1-4 Seizures may be the presenting symptom of a brain tumor, or they may occur later during the disease. Only the recurrence of seizures justifies the diagnosis of epilepsy and the use of anticonvulsants.5
- 1 January 2010
- Published by Springer Nature
- p. 1255-1263
Angelman Syndrome